aabb 2013 annual report · recommendations for red blood cell, or rbc, transfusion ... the...

fiscal year

AnnualReport

fiscal year

Letter From Leadership ....................................................................................3AABB’s Mission, Vision and Core Values .........................................................4Membership Demographics .............................................................................5FY 2013 Association Accomplishments ............................................................6National Blood Foundation ...............................................................................9AABB Board of Directors (2012-2013) .......................................................... 10A Look Ahead: AABB’s Strategic Goal Statements ........................................11FY 2013 Financial Highlights .........................................................................12

Table ofContents

2FISCAL YEAR 2013 ANNUAL REPORT


fiscal year

letter from leadership

Many forces are reshaping the transfusion medicine and cellular therapy field for patients, donors, blood centers, hospitals, academia and industry. We are very

proud of the adaptations and investments AABB has made to support its members and customers in this changing landscape.

The past 12 months demonstrates AABB’s ability to keep pace with the changing times to ensure that the individuals and institutions we serve can continue to provide the highest level of quality care to patients and donors. Most notably, in fiscal year 2013, we strengthened the organizational structure of the AABB Center for Cellular Therapies by hiring Naynesh Kamani, MD, an accomplished physician scientist with clinical research experience in hematopoietic stem cell transplantation and clinical translational research.

We also furthered our patient blood management, or PBM, program through the leadership provided by members of the AABB PBM Standards Program Unit and other key external stakeholders and partners. We created the Transfusion Safety and PBM subsection — offering an opportunity for transfusion safety officers and other clinicians and program leaders to collaborate on the development of a multidisciplinary approach to optimizing the care of patients who might need a transfusion. This section is thriving with more than 190 individuals participating.

Additionally, we moved forward with our recipient and donor hemovigilance programs and addressed regulatory developments. AABB’s success in bringing together

experts and thought leaders resulted in the U.S. Food and Drug Administration’s recognition of the Abbreviated Blood Donor History Questionnaire, Version 1.3, that was prepared by the AABB Donor History Task Force, as well as the development of new and updated emerging infectious disease fact sheets by the AABB Transfusion Transmitted Diseases Committee. AABB also convened workshops designed to receive critical feedback from our members and key constituents to shape the association’s policies and standards, including one focusing on transfusion-related acute lung injury.

Through effective advocacy and our education offerings, AABB provides leading-edge information, access to expert knowledge and dissemination of best practices. The accomplishments documented in this report exhibit our commitment to the care and safety of patients and donors.

Sincerely,

Graham Sher, MD, PhD President-Elect

Miriam A. MarkowitzChief Executive Officer


fiscal year

aaBB’s mission, Vision and core Values

MissionAABB advances the practice and standards of transfusion medicine and cellular therapies to optimize patient and donor care and safety.

VisionAABB will be the pre-eminent knowledge-based organization focused on improving health through advancing the science and practice of transfusion medicine and cellular therapies.

Core ValuesAABB will fulfill its mission and vision through adherence to its core values: • the pursuit of excellence • focus on the patient and donor • integrity • transparency • consensus building • innovation

Accreditation Statistics:

•AABB has approximately 800 active volunteer assessors

•AABB assessors come from 13 countries

•AABB’s accreditation program and assessor training program were reaccredited in FY 2013 for four years by the International Society for Quality in Health Care

•AABB accredited facilities are located in 29 countries

FACTS & FIGURES


fiscal year

memBership demographics

statistics for fiscal year 2013 (oct. 1, 2012 through sept. 30, 2013)

AABB Individual Members:5,680 Health Care Professionals

1,561 Physicians

213 Residents

157 e-Members

294 Emeritus Members

AABB Institutional Members: 869 Transfusion Services 210 Blood Centers 217 Hospital Blood Banks 164 Specialty Facilities

69 Affiliates/Corporate Affiliates

TRANSFUSION Statistics:•Renewal rate (includes members and nonmembers) was 95%

•Full-article downloads were 449,708, an increase of 6.4%

•Readership in China increased 26%

•www.transfusion.org page views were 1,556,627

•More than 55% of articles were from non-U.S. authors — individuals from Australia, Canada, France, Germany and United Kingdom account for the most non-U.S. contributors

Angola

Argentina

Belgium

Botswana

Brazil

Canada

China

Colombia

Cyprus

Dominican Republic

Greece

Honduras

Hong Kong

India

Italy

Japan

Lesotho

Malawi

Mauritius

Mozambique

Netherlands

Philippines

Poland

Rwanda

Saudi Arabia

Singapore

South Africa

Swaziland

Switzerland

Taiwan

Tanzania

United Kingdom

Zimbabwe

Number of countries (outside of U.S.) visited by AABB’s staff and assessors for professional purposes in FY 2013 = 33+

FACTS & FIGURES

FACTS & FIGURES


fiscal year

fy 2013 associationaccomplishments

Patient Blood Management

In pressing forward with its commitment to PBM, AABB developed new tools, programs and materials that assist members in adopting evidence-based, multidisciplinary approaches to optimizing the care of patients who might need transfusion.

Standards for Patient Blood Management ProgramsAfter collecting comments in response to the posting of a PBM best practices document, AABB formed a PBM Standards Program Unit to develop standards for PBM using AABB’s rigorous standard-setting process. The PBM Standards Program Unit — composed of individuals with extensive clinical expertise and experience in the oversight of PBM-related activities — published draft standards in a quality framework for public comment.

Red Cell Guideline Data CardAfter publishing clinical practice guidelines in the

“Annals of Internal Medicine,” AABB distilled the recommendations for red blood cell, or RBC, transfusion into a convenient laminated data card. This important information also appears in AABB’s new PBM smartphone app. Development of clinical practice guidelines for platelet transfusion is underway.

Transfusion Safety Officers and PBM CoordinatorsA new Transfusion Safety and PBM subsection of the

Transfusion Medicine Section met for the first time at the 2012 AABB Annual Meeting. Since then, members of the section have met on a bimonthly basis to discuss the latest developments in PBM, present at conferences within the U.S., participate in creation of several educational offerings and network with PBM professionals around the world.

Smartphone AppAABB launched a smartphone app that provides easy

access to the distilled RBC transfusion guidelines and the entire Circular of Information for the “Use of Human Blood and Blood Components,” as well as a file on managing suspected transfusion reactions. More content is planned to support clinicians in the field.

EducationAABB made available an array of educational

offerings including PBM webinars, books, a preconvention physician’s workshop and AABB Annual Meeting sessions. Development of online learning modules continued as well.

During the past 12 months, AABB has made great strides to further enhance its mission, especially with regard to its key strategic initiatives — patient blood management, or PBM, cellular therapies, or CT, and hemov-igilance. These initiatives are designed to ensure that members continue to have access to education and support services that help them provide optimal quality care to patients and donors.

fiscal year



Center for Cellular Therapies

As with PBM, AABB is keeping pace with changes in the cellular therapies, or CT, arena to ensure that members are well-positioned to meet the challenges of the future. To accomplish this goal, AABB has broadened its scope to encompass the rapidly growing novel and regenerative cellular therapies field.

AABB Center for Cellular TherapiesDuring the last year, Naynesh Kamani, MD, joined

AABB as division director of the AABB Center for Cellular Therapies. He has rich clinical and research experience in hematopoietic stem cell transplantation and already has guided efforts to help the many members engaged in the cellular therapies field.

CT Regulatory ToolkitAABB issued the first in a four-part series of electronic

tools intended to help CT professionals prepare documents for submission to the U.S. Food and Drug Administration. The first part of the series, “Pre-IND Meeting Request and Briefing Package Templates,” contains step-by-step instructions and templates to help guide users through the pre-IND submission and meeting process. (Three addition-al tools were released in FY 2014.)

Clinical StandardsAABB’s sixth edition of Standards for Cellular Therapy

Services now includes requirements that address clinical activities in the hematopoietic stem cell transplantation setting: patient consent, patient care, preparation for prod-uct administration, clinical outcomes reporting and other relevant aspects of clinical care.

CT Webinar SeriesThroughout the year, convenient webinars covered a

variety of relevant topics, including global compliance and policy, quality assurance and technical know-how. The recorded presentations are archived as a valuable resource.

Podcast SeriesMembers now can get their science “on the go” through

podcasts on a wide variety of topics including compliance with standards requirements, ethical debates and the sci-ence behind testing methods and innovations.

Cellular Therapies SectionMembers of the CT Section and its seven subsections

have been collaborating to develop resources to assist their colleagues. One such project is on the electronic tracking of consumables and another involves training resources.

Cellular Therapy Members by CredentialsAs of Sept. 30, 2013

None provided(25%)

Technologist(47%)

MD(21%)

PhD(6%)

RN(2%)

N = 417(Total number of CT Section members)

FACTS & FIGURES


fiscal year

Hemovigilance

A third area in which AABB has made significant strides to enhance patient safety is that of biovigilance — specifically hemovigilance — through the AABB Center for Patient Safety and the AABB United States Donor Hemovigilance Program.

AABB Center for Patient SafetyThe center is AABB’s patient safety organization,

or PSO, and collects and analyzes data about adverse reactions and incidents related to blood transfusions. An increasing number of hospitals have joined the AABB Center for Patient Safety to receive support with their internal hemovigilance activities and to participate in targeted interventions and analyses. By becoming a member, a hospital can participate in confidential benchmarking analytics and peer-to-peer discussions in support of transfusion safety and patient outcomes.

Reporting and AnalysisThroughout FY 2013, the AABB Center for Patient Safety worked with 50 hospitals to provide confidential hemovigilance reporting and assistance with respiratory adverse event analysis; conducted a case study validation of adverse reaction reporting; and led quarterly “Safe Table” meetings and conference calls to discuss concerns and solutions associated with adverse events in transfusion medicine. Also during this time period, the “AABB Center for Patient Safety Newsletter” was launched, with AABB’s PSO membership receiving the first two issues of this quarterly e-communication.

Quarterly Benchmarking ReportsThe AABB Patient Safety Organization released four quarterly benchmarking reports to its center members, comparing adverse reaction and incident data within the PSO. Most recent analyses have included comparisons of component wastage.

AABB United States Donor Hemovigilance ProgramAABB continued its efforts to promote donor-centered

hemovigilance as well. In the last 12 months, AABB’s highly successful and engaged donor hemovigilance working group expanded to include the early-adopter blood centers that incorporated the AABB donor adverse reaction definitions and submitted 2012 data. These pioneers have a report analyzing their aggregated data in the pipeline for release in 2014.

In addition to its hemovigilance-related achievements, AABB authored the United States’ Department of Health and Human Services 2011 National Blood Collection and Utilization Survey Report, which is available online at www.aabb.org.



fiscal year

national Blood foundation

A s part of its mission to improve health, AABB supports research through its National Blood Foundation, or NBF, program. Established in 1983, the NBF has distributed nearly

$8 million to approximately 200 early-career scientists. In FY 2013 alone, the NBF awarded a total of $375,000 to five recipients. Funds are raised annually from corporations, blood centers, foundations and individuals.

Recently, a study funded in part by the NBF resulted in a method to address the shortage of blood lacking the Vel blood group antigen. In addition to fostering scientific advances, NBF brings together leaders in the transfusion medicine and cellular therapy community — through its annual Leadership Forum and as part of AABB’s CEO Summit — to address critical issues affecting the field.

Membership continues to grow, with three organizations joining its Partners program in FY 2013: Canadian Blood Services, the Blood Bank of Delmarva and LIFELINE Blood Services. Additionally, Cerus Corporation has pledged to join NBF’s Council on Research and

Development, or CORD, program in FY 2014. The NBF also continues to see high registration numbers for its events, as well as generous corporate funding.

As the foundation’s membership expands, so do the scientific areas it supports. Applications regarding studies on cellular therapies have increased in number. Almost half of the grants awarded this year supported cellular therapy-related investigations. In FY 2013, the NBF Board of Trustees added patient blood management to the categories of studies it will fund in FY 2014 — that is, studies of evidence-based, multidisciplinary approaches for optimizing the care of patients who might need a transfusion.

For more information on the NBF, individuals are invited to visit www.aabb.org/nbf or contact a representative at [email protected] or +1.301.215.6552.

2013 NBF Grant Applications ReceivedResearch Content Area U.S. and Non-U.S.

2 grants(6%)

32 grants(94%)

4 grants(12%)

10 grants(29%)

20 grants(59%)

TM CT Infectious Disease Non-U.S. U.S.

FACTS & FIGURES


fiscal year

AABB Board of directors2012 – 2013

PRESIDENTSusan L. Stramer, PhD American Red Cross Gaithersburg, Md.

PAST PRESIDENTDarrell J. Triulzi, MD Institute for Transfusion Medicine Pittsburgh, Pa.

PRESIDENT-ELECTGraham Sher, MD, PhD Canadian Blood Services Ottawa, Ontario Canada VICE PRESIDENTLynne Uhl, MD Beth Israel Deaconess Medical CenterBoston, Mass.

SECRETARYDonna Regan, MT(ASCP)SBB SSM Cardinal Glennon Children’s Hospital St. Louis, Mo.

TREASURER (FINANCE COMMITTEE CHAIR) Zbigniew Szczepiorkowski, MD, PhD, FCAP Dartmouth-Hitchcock Hospital CenterDepartment of PathologyLebanon, N.H. (Also served as At-Large Director position 1)

AT-LARGE DIRECTORS Position 1Zbigniew Szczepiorkowski, MD, PhD, FCAP Dartmouth-Hitchcock/ Hospital Center Lebanon, N.H.

Position 2Michael Murphy, MD, FRCP, FRCPathNational Blood ServiceJohn Radcliffe HospitalUnited Kingdom

Position 3Beth Shaz, MD New York Blood CenterNew York, N.Y.

Position 4Susan Johnson, MSTM(ASCP)SBBBloodCenter of Wisconsin, Inc. Milwaukee, Wis.

Position 5Susan Roseff, MD Virginia Commonwealth University Medical Center Department of Pathology Richmond, Va. Position 6Jeannie Callum, MD, FRCPC, CTBSSunnybrook Health Sciences CentreDepartment Clinical Pathology/ Blood BankToronto, Ontario Canada

Position 7Joanne Becker, MD Roswell Park Cancer InstituteBuffalo, N.Y.

Position 8E. Mary O’Neill, MD American Red Cross Blood ServicesDedham, Mass.

Position 9Nora Hirschler, MD Blood Centers of the PacificSan Francisco, Calif.

Position 10David McKenna, Jr., MD University of MinnesotaMolecular and Cellular TherapeuticsSt. Paul, Minn.

TRANSFUSION MEDICINE SECTION REPRESENTATIVE (DIRECTOR)Eva Quinley, MS, MT(ASCP)SBB, CQA(ASQ) New York Blood Center New York, N.Y.

CELLULAR THERAPIES SECTION REPRESENTATIVE (DIRECTOR)Doug Padley, MT(ASCP) Mayo ClinicRochester, Minn. APPOINTED DIRECTORDarin J. Weber, PhD Mesoblast, Inc.New York, N.Y.

Jonathan Waters, MDMagee Women’s Hospital of UPMC Pittsburgh, Pa.

EX-OFFICIO DIRECTORMiriam A. MarkowitzCEO - AABBBethesda, Md. (May 2013 - Present)

Karen L. Shoos, JDCEO - AABBBethesda, Md.(Retired as CEO in May 2013)


fiscal year

AABB Center for Cellular TherapiesPosition AABB as the leading professional association for

standards setting, accreditation and quality management as well as the premier resource for education and regulatory information in cellular and regenerative therapies.

Patient Blood Management (PBM)Position AABB as the leader in PBM for clinical

professionals, health care institutions, and the broader health sector through the development of PBM-specific offerings (e.g., standards, accreditation, education, con-sulting, advocacy).

Blood Banking and Transfusion MedicineAABB, through ongoing innovation, will retain its pre-

mier quality management brand with respect to standards setting, accreditation, education, regulatory and advocacy for blood banking and transfusion medicine.

International FocusMaximize AABB’s value to international professionals,

institutions and government agencies by effectively pro-viding relevant resources and services in cellular therapies, blood banking and transfusion medicine.

Community and Health ImpactPosition AABB to enhance its value to members and the

broader community through impactful research, outcomes programs and advocacy to improve donor and patient care.

a look aheadAABB’s Strategic Goal Statements

Health care, specifically in the U.S., is undergoing historic change. To uphold the association’s rich legacy and ensure its relevance for years to come, the AABB Board of Directors, throughout FY 2013, focused on mapping AABB’s strategic direction — recognizing that AABB must remain agile and anticipate both the opportunities and challenges facing its membership.

The AABB Board of Directors identified priorities and developed goal statements to capture this strategy. These goals align with the association’s mission and pursuit of its vision.

AABB Publication Statistics:

•22 new or “coming soon” titles were added to AABB’s offerings

•Content totaled 1,972 published pages of varying dimensions

•Content for these books was provided by 99 volunteer contributors

•AABB books are read in at least 91 countries around the world

•170 digital downloads are available

FACTS & FIGURES


fy 13 financial highlights

AMERICAN ASSOCIATION OF BLOOD BANKS STATEMENTS OF FINANCIAL POSITION

SEPTEMBER 30, 2013 and 2012

See accompanying Notes to Financial Statements. (3)

2013 2012ASSETS

CURRENT ASSETSCash and Cash Equivalents 210,882$ 476,910$Accounts Receivable (Less Allowance of $46,934 and $25,220 in 2013 and 2012, Respectively) 870,435 2,151,942Contributions Receivable, Current Portion 195,414 274,038National Blood Exchange Accounts Receivable (Less Allowance of $28,066 and $99,713 in 2013 and 2012, Respectively) 2,708,257 2,287,571Inventory 543,752 480,779Deferred Costs 1,546,749 1,611,655Prepaid Expenses and Other 219,631 286,767

Total Current Assets 6,295,120 7,569,662

CONTRIBUTIONS RECEIVABLE, Less Current Portion (Less Unamortized Discount of $1,193 and $3,321 in 2013 and 2012,

Respectively) 10,807 8,679

INVESTMENTS 13,039,289 12,629,531

CERTIFICATES OF DEPOSIT - 259,750

PROPERTY AND EQUIPMENTFurniture and Equipment 2,245,000 2,039,150Leasehold Improvements 598,619 598,619Software 4,001,870 3,471,720Software Development in Progress 576,001 564,259

7,421,490 6,673,748Less: Accumulated Depreciation and Amortization (5,870,675) (5,307,156)

Total Property and Equipment 1,550,815 1,366,592

OTHER ASSETSSecurity Deposit 47,921 47,921Accrued Interest 19,937 28,253

Total Other Assets 67,858 76,174

Total Assets 20,963,889$ 21,910,388$

LIABILITIES AND NET ASSETS

CURRENT LIABILITIESAccounts Payable and Accrued Expenses 2,119,339$ 1,525,696$National Blood Exchange Accounts Payable 2,514,543 3,088,132Unearned Revenue 5,847,035 6,075,316Capital Lease 29,966 - Deferred Lease Incentive 43,603 43,603

Total Current Liabilities 10,554,486 10,732,747

OTHER LIABILITIESCapital Lease, Less Current Portion 68,178 - Deferred Rent 192,519 205,966Deferred Lease Incentive, Less Current Portion 90,839 134,441

Total Other Liabilities 351,536 340,407

Total Liabilities 10,906,022 11,073,154

NET ASSETSUnrestricted 9,402,365 10,097,860Temporarily Restricted 655,502 739,374

Total Net Assets 10,057,867 10,837,234

Total Liabilities and Net Assets 20,963,889$ 21,910,388$

aabb 2013 annual report · recommendations for red blood cell, or rbc, transfusion ... the...

Documents